Unfortunately, the delayed rise in SCr level after AKI develops, along with the complexity and intermittent nature in measuring renal injury biomarkers such as liver fatty acid binding protein (LFABP), cystatin C (CysC), neutrophil gelatinase-associated apolipoprotein (NGAL), etc. [6], makes them impractical for point-of-care monitoring and early detection of AKI. The gene discussed is LCN2; the disease is acute kidney injury.